Metrics as of 10/16/2026, 06:24 AM (Berlin time), refresh in progress.
Adial Pharmaceuticals Stock
Adial Pharmaceuticals, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Cary John Claiborne
- Employees
- 5
- Market cap
- $8 M
- IPO
- 27/07/2018
Adial Pharmaceuticals, Inc. is a biopharmaceutical enterprise operating at the clinical stage, dedicated to researching and developing innovative therapeutic options for the management and prevention of addiction and associated disorders. Its primary investigational compound, AD04, functions as a selective serotonin-3…
Adial Pharmaceuticals stock: price history
1D
+4.7%
1W
-20.9%
1M
-37.2%
6M
+93.8%
YTD
-42.9%
1Y
-67.8%
2Y
-86.8%
5Y
-99.9%
10Y
–
Next earnings date
Next earnings date
18/11/2026 (in 32 days)
Volatility around earnings
~34% weaker price swings than usual
Ask the agents about Adial Pharmaceuticals
Analyst assessment of Adial Pharmaceuticals
PRICE TARGET LOW
US$6.00
CONSENSUS
US$8.50
MEDIAN
US$8.50
PRICE TARGET HIGH
US$11.00
0
STRONG BUY
3
BUY
0
HOLD
0
SELL
0
STRONG SELL
3
TOTAL · Buy
As of: 30/09/2025
Adial Pharmaceuticals stock metrics
P/E
-0.19
P/B
93.03
EV/EBITDA
0.35
RETURN ON EQUITY
-33,326.3%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
80.4%
FLOAT SHARES
2,111,111
AVG. DAILY VOLUME (30D)
44,753
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Adial Pharmaceuticals stock
What does Adial Pharmaceuticals do?
Adial Pharmaceuticals, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Cary John Claiborne, the company employs around 5 people.
The IPO was on 27/07/2018; the stock trades on NASDAQ under the ticker ADIL.
What do analysts say about Adial Pharmaceuticals stock?
3 analysts rate the stock, the consensus is Buy (as of 30/09/2025).
The average price target is US$8.50, ranging from US$6.00 to US$11.00, with a median of US$8.50.
This is an external assessment, not a statement by Market Jury.
When does Adial Pharmaceuticals report next?
The next earnings date is 18/11/2026.
Around past earnings, price swings were roughly -34% stronger than usual.
Does Adial Pharmaceuticals pay a dividend?
No, Adial Pharmaceuticals currently does not pay a dividend.
Which stocks are comparable to Adial Pharmaceuticals?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Adial Pharmaceuticals stock analyzed?
Clicking "Analyze stock" lets five strategies assess Adial Pharmaceuticals against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.